Novo and Orbis Sign Billion-Dollar Drug Development Partnership

Danish pharma Novo has partnered with biotech Orbis in a billion-dollar deal to develop new medicines. The collaboration signals continued investment in R&D pipelines, though specific therapeutic areas and financial terms remain undisclosed. This is a notable corporate development in the pharmaceutical sector, potentially impacting future product portfolios.